MEK and the inhibitors: from bench to bedside

Four distinct MAP kinase signaling pathways involving 7 MEK enzymes have been identified. MEK1 and MEK2 are the prototype members of MEK family proteins. Several MEK inhibitors are in clinical trials. Trametinib is being evaluated by FDA for the treatment of metastatic melanoma with BRAF V600 mutati...

Descripción completa

Detalles Bibliográficos
Autores principales: Akinleye, Akintunde, Furqan, Muhammad, Mukhi, Nikhil, Ravella, Pavan, Liu, Delong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3626705/
https://www.ncbi.nlm.nih.gov/pubmed/23587417
http://dx.doi.org/10.1186/1756-8722-6-27
_version_ 1782266235094827008
author Akinleye, Akintunde
Furqan, Muhammad
Mukhi, Nikhil
Ravella, Pavan
Liu, Delong
author_facet Akinleye, Akintunde
Furqan, Muhammad
Mukhi, Nikhil
Ravella, Pavan
Liu, Delong
author_sort Akinleye, Akintunde
collection PubMed
description Four distinct MAP kinase signaling pathways involving 7 MEK enzymes have been identified. MEK1 and MEK2 are the prototype members of MEK family proteins. Several MEK inhibitors are in clinical trials. Trametinib is being evaluated by FDA for the treatment of metastatic melanoma with BRAF V600 mutation. Selumetinib has been studied in combination with docetaxel in phase II randomized trial in previously treated patients with advanced lung cancer. Selumetinib group had better response rate and progression-free survival. This review also summarized new MEK inhibitors in clinical development, including pimasertib, refametinib, PD-0325901, TAK733, MEK162 (ARRY 438162), RO5126766, WX-554, RO4987655 (CH4987655), GDC-0973 (XL518), and AZD8330.
format Online
Article
Text
id pubmed-3626705
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-36267052013-04-16 MEK and the inhibitors: from bench to bedside Akinleye, Akintunde Furqan, Muhammad Mukhi, Nikhil Ravella, Pavan Liu, Delong J Hematol Oncol Review Four distinct MAP kinase signaling pathways involving 7 MEK enzymes have been identified. MEK1 and MEK2 are the prototype members of MEK family proteins. Several MEK inhibitors are in clinical trials. Trametinib is being evaluated by FDA for the treatment of metastatic melanoma with BRAF V600 mutation. Selumetinib has been studied in combination with docetaxel in phase II randomized trial in previously treated patients with advanced lung cancer. Selumetinib group had better response rate and progression-free survival. This review also summarized new MEK inhibitors in clinical development, including pimasertib, refametinib, PD-0325901, TAK733, MEK162 (ARRY 438162), RO5126766, WX-554, RO4987655 (CH4987655), GDC-0973 (XL518), and AZD8330. BioMed Central 2013-04-12 /pmc/articles/PMC3626705/ /pubmed/23587417 http://dx.doi.org/10.1186/1756-8722-6-27 Text en Copyright © 2013 Akinleye et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Akinleye, Akintunde
Furqan, Muhammad
Mukhi, Nikhil
Ravella, Pavan
Liu, Delong
MEK and the inhibitors: from bench to bedside
title MEK and the inhibitors: from bench to bedside
title_full MEK and the inhibitors: from bench to bedside
title_fullStr MEK and the inhibitors: from bench to bedside
title_full_unstemmed MEK and the inhibitors: from bench to bedside
title_short MEK and the inhibitors: from bench to bedside
title_sort mek and the inhibitors: from bench to bedside
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3626705/
https://www.ncbi.nlm.nih.gov/pubmed/23587417
http://dx.doi.org/10.1186/1756-8722-6-27
work_keys_str_mv AT akinleyeakintunde mekandtheinhibitorsfrombenchtobedside
AT furqanmuhammad mekandtheinhibitorsfrombenchtobedside
AT mukhinikhil mekandtheinhibitorsfrombenchtobedside
AT ravellapavan mekandtheinhibitorsfrombenchtobedside
AT liudelong mekandtheinhibitorsfrombenchtobedside

Ejemplares similares